ArticlePloS one2012
Probing high affinity sequences of DNA aptamer against VEGF165.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 139 citations in OpenAlex.
- Aptamer-based DNA nanoswitches for multiplexed protein detection.Chemical communications (Cambridge, England) · 2026Article
- Aptamer-based DNA nanoswitches for multiplexed protein detection.bioRxiv : the preprint server for biology · 2026Article
- Integrating Magnetic Bead-Based SELEX withACS omega · 2025Article
- Gold Nanoprism Enhanced SERS Aptasensor for Simultaneous Detection of Thrombin and VEGF.Sensors and actuators. B, Chemical · 2025Article
- Recent Advances in Aptamer-Based Biosensors for Bacterial Detection.Biosensors · 2024Review
- Rational Approach to Optimizing Conformation-Switching Aptamers for Biosensing Applications.ACS sensors · 2024Article
- VEGF Detection via Impedance Spectroscopy on Surface Functionalized Interdigitated Biosensor.Journal of functional biomaterials · 2023Article
- A comparative study of aptamer isolation by conventional and microfluidic strategies.The Analyst · 2023Article
- bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.International journal of molecular sciences · 2023Review
- Targeting a conserved structural element from the SARS-CoV-2 genome using l-DNA aptamers.RSC chemical biology · 2022Article
- Selection and Characterization of Vimentin-Binding Aptamer Motifs for Ovarian Cancer.Molecules (Basel, Switzerland) · 2021Article
- High-Throughput Selection and Characterisation of Aptamers on Optical Next-Generation Sequencers.International journal of molecular sciences · 2021Review
- Performance Analysis of Non-Interferometry Based Surface Plasmon Resonance Microscopes.Sensors (Basel, Switzerland) · 2021Article
- Comparison of protein capture from a human cancer cell line by genomic G-quadruplex DNA sequences toward aptamer discovery.Analytical and bioanalytical chemistry · 2021Article
- Evidence-Based View of Safety and Effectiveness of Prokineticin Receptors Antagonists during Pregnancy.Biomedicines · 2021Article
- Lipid-oligonucleotide conjugates for bioapplications.National science review · 2020Article
- Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.3 Biotech · 2020Review
- Logic Gates Based on DNA Aptamers.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Dimeric and Multimeric DNA Aptamers for Highly Effective Protein Recognition.Molecules (Basel, Switzerland) · 2020Review
- Recent advances in aptamer-based sensors for breast cancer diagnosis: special cases for nanomaterial-based VEGF, HER2, and MUC1 aptasensors.Mikrochimica acta · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor (VEGF(165)) is a potent angiogenic mitogen commonly overexpressed in cancerous cells. It contains two main binding domains, the receptor-binding domain (RBD) and the heparin-binding domain (HBD). This study attempted to identify the specific sequences of the VEa5 DNA aptamer that exhibit high binding affinity towards the VEGF(165) protein by truncating the original VEa5 aptamer into different segments. Using surface plasmon resonance (SPR) spectroscopy for binding affinity analysis, one of the truncated aptamers showed a >200-fold increase in the binding affinity for HBD. This truncated aptamer also exhibited high specificity to HBD with negligible binding affinity for VEGF(121), an isoform of VEGF lacking HBD. Exposing colorectal cancer cells to the truncated aptamer sequence further confirmed the binding affinity and specificity of the aptamer to the target VEGF(165) protein. Hence, our approach of aptamer truncation can potentially be useful in identifying high affinity aptamer sequences for the biological molecules and targeting them as antagonist for cancer cell detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.